Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hemophilia A, any severity, with documented history of high-titer inhibitor (\>5BU); current use of bypassing agents (PCCs, aPCCs or rFVIIa) for treatment of bleeds; \>/= 6 bleeds requiring bypassing therapy in the previous 6 months~Exclusion Criteria:~* concomitant immune tolerance therapy; clinically symptomatic liver disease, platelet count less than 100,000

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On-demand first (Type: OTHER): Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
- Prophylaxis first (Type: OTHER): Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).